SCYNEXIS Secures $24.8M from GSK, Advances Lead Antifungal Program SCY-247, and Extends Nasdaq Compliance
SCYX sits 37% above its 52-week low of $0.565.
Summary
SCYNEXIS received a significant $24.8 million payment from GSK, improving its liquidity and enabling continued development of its lead antifungal candidate, SCY-247, which showed positive Phase 1 results and is advancing to Phase 2.
Key Events · Financing and Capital Events · SCYX
-
Secured $24.8 Million from GSK
SCYNEXIS received a one-time, non-refundable payment of $24.8 million from GSK in November 2025, following the termination of the Phase 3 MARIO study for ibrexafungerp. This payment significantly enhances the company's cash position.
-
Improved Financial Outlook and Liquidity
The company reported a reduced net loss of $8.6 million in 2025, a substantial improvement from $21.3 million in 2024. With $56.3 million in cash, cash equivalents, and investments, SCYNEXIS projects sufficient capital to fund operations for at least 12 months.
-
Positive Clinical Progress for SCY-247
The oral formulation of SCY-247 completed Phase 1 studies with positive safety, tolerability, and pharmacokinetic results. An intravenous formulation Phase 1 study was initiated in Q1 2026, with a Phase 2 proof-of-concept study planned for 2026 in Invasive Candidiasis.
-
Regulatory Designations for SCY-247
SCY-247 has been granted Qualified Infectious Disease Product (QIDP) status and Fast Track designations by the FDA, which could provide regulatory exclusivity and expedite the review process if approved.
Analysis · SCYX · Life Sciences
SCYNEXIS has significantly bolstered its financial position and advanced its key pipeline asset. The $24.8 million payment from GSK, following the termination of the MARIO study, provides critical liquidity and a projected 12-month operating runway. This cash infusion is substantial for a company of this size. Concurrently, positive Phase 1 results for SCY-247, along with its progression to an intravenous formulation study and a planned Phase 2 trial, underscore the potential of its lead antifungal program. The company also successfully navigated a Nasdaq delisting threat by securing an extension, with a reverse stock split as a potential future measure. The dismissal of prior legal actions further removes a significant overhang. Investors should monitor the progress of SCY-247's clinical trials and GSK's relaunch of BREXAFEMME for continued positive momentum.
At the time of this filing, SCYX was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.5M. The 52-week trading range was $0.57 to $1.31. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.